The expression primary T790M overall survivalimertinib, which has emerged in the realm of precision cancer medicine, is now a pivotal point of discussion.The finding of the T790M change in lung cancer patients who have not been previously treated with overall survivalimertinib, a precision therapy for EGFR-altered NSCLC (NSCLC), refers to this phrase.This article delves into the significance of this finding, exploring how it effects patient treatment and the development of tailored treatment strategies.After initial treatment with EGFR TKMs (TKMs), the T790M change often arises as a follow-on change in EGFR-altered…
